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CD80 and CD86 costimulatory molecules regulate crescentic
glomerulonephritis by different mechanisms.
Background. CD80 and CD86 costimulatory molecules have
been shown to affect the induction of Th1-mediated crescentic
antiglomerular basement membrane (GBM) antibody-initiated
glomerulonephritis (GN). The aim of the current studies was to
define the mechanisms by which CD80 and CD86 regulate the
development of this disease.
Methods. Anti-GBM GN was induced in CD80−/−,
CD86−/−, and CD80/86−/− mice, as well as in C57BL/6 con-
trols. Renal injury and immune responses were assessed after 21
days. To examine whether costimulation by OX40-ligand com-
pensates for the absence of CD80 and CD86 in inducing GN,
OX40-ligand was blocked in wild-type and CD80/86−/− mice.
Results. Crescentic GN and glomerular accumulation of
CD4+ T cells and macrophages were attenuated in CD80−/−
mice, correlating with significantly enhanced apoptosis and de-
creased proliferation of spleen CD4+ T cells. GN was exacer-
bated in CD86−/− mice, which was associated with attenuated
IL-4 and enhanced IFN-c levels. In contrast, CD80/86−/− mice
developed crescentic GN similar to that in controls. Inhibition
of OX40-ligand exacerbated GN in wild-type mice by enhanc-
ing IFN-c production, and attenuated disease in CD80/86−/−
mice by reducing glomerular CD4+ T-cell and macrophage ac-
cumulation.
Conclusion. CD80 is pathogenic in crescentic GN by enhanc-
ing survival and proliferation of CD4+ T cells, whereas CD86
is protective by enhancing Th2 and attenuating Th1 responses.
Furthermore, in the presence of CD80 and CD86, OX40-ligand
attenuates, whereas in their absence it enhances GN, suggesting
that, in the absence of CD80 and CD86, the OX40/OX40-ligand
pathway is an alternative costimulatory pathway in inducing
crescentic GN.
Glomerulonephritis (GN) is a major cause of end-stage
renal failure. Immune responses to self or foreign anti-
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gens (Ag) in glomeruli result in many different forms of
GN, with the most severe and rapidly progressive type
being crescentic nephritis. While some valuable insight
into the pathogenesis of crescentic GN has been pro-
vided by observations of human immunopathology, much
of our insight into the mechanisms of crescentic nephritis
comes from experimental models. The most widely used
animal model of crescentic GN is antiglomerular base-
ment membrane (GBM) antibody (Ab)-initiated GN,
where heterologous anti-GBM Ab acts as a planted Ag
in glomeruli. In C57BL/6 mice, the development of cres-
centic anti-GBM GN is directed by CD4+ Th1 cells, at-
tenuated by Th2 cytokines, and is strongly dependent on
glomerular infiltration of delayed type hypersensitivity
(DTH) effectors, CD4+ T cells, and macrophages, while
it is independent of autologous Ab deposited along the
GBM [1–4].
Optimal activation of naı¨ve CD4+ T cells requires
engagement of the T-cell receptor, as well as nonantigen-
specific costimulatory signals. The best-characterized cos-
timulatory signal is provided by CD80 (B7-1) and CD86
(B7-2) expressed on antigen-presenting cells. Interaction
between these ligands and T-cell receptors, CD28 and
CTLA-4, either enhances or down-regulates T-cell re-
sponses, respectively [5–7]. CD80 and CD86 can affect
disease outcome by promoting T-cell survival and pro-
liferation, and by altering the Th1/Th2 balance. For ex-
ample, disruption of CD28/B7 costimulation inhibited
proliferation of Ag-specific T cells and, consequently,
reduced the severity of experimental autoimmune en-
cephalomyelitis (EAE) [8]. In addition, the absence of
CD80/86 costimulation exacerbated autoimmune dia-
betes due to reduced IL-4 and enhanced IFN-c produc-
tion [9], while it attenuated EAE due to the inhibition of
Th1 and up-regulation of Th2 cytokines [10]. Studies in-
vestigating the individual roles of CD80 and CD86 have
shown that these molecules can have distinct or over-
lapping functions during an adaptive immune response
depending on the disease model studied and the immune
mechanisms involved. For example, blockade of CD80 or
CD86 attenuated or enhanced the development of EAE,
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respectively [11], while combined blockade of both CD80
and CD86 attenuated collagen-induced arthritis [12]. Fur-
thermore, it has been shown that CD80/86 costimulation
is not always required for the development of T-cell–
mediated diseases, suggesting the existence of alternative
costimulatory pathways, such as the OX40/OX40-ligand
pathway, which has been demonstrated to be of particu-
lar importance in T-cell responses and to synergize with
CD28 costimulation, but at the same time to provide a
CD28-independent signal [13–17].
The role of CD80 and CD86 costimulation has also
been investigated in several models of GN, including
experimental autoimmune GN (EAG) [18, 19], lupus
nephritis [20–24], renal transplantation [25], and anti-
GBM globulin GN [26]. In the anti-GBM GN model,
inhibition of both CD80 and CD86 had no effect on
disease development, while anti-CD80 mAb treatment
attenuated, and anti-CD86 treatment exacerbated, renal
injury [26]. These results, however, could not be explained
by changes in humoral or cell-mediated systemic immu-
nity. The current studies aimed to define the mechanisms
by which CD80 and CD86 regulate crescentic anti-GBM
GN by using mice genetically deficient in either CD80 or
CD86, as well as both CD80 and CD86, and to investigate
the role of an alternative costimulatory molecule, OX40-
ligand (OX40-L), in the absence of CD80 and CD86. They
demonstrate that CD80 has a pathogenic role in crescen-
tic GN by promoting survival and proliferation of CD4+
T cells, while CD86 has a protective role by promoting
Th2 and attenuating Th1 responses. They also show that
crescentic GN can develop independently of CD80 and
CD86, and that the OX40/OX40-L pathway is an alter-
native costimulatory pathway for mediating immune re-
sponses that induce crescentic GN in the absence of both
CD80 and CD86.
METHODS
Experimental design
Eight- to 10-week-old male mice were used for ex-
periments. Mice deficient in CD80 (CD80−/−), CD86
(CD86−/−), and CD80 and CD86 (CD80/86−/−) on a
C57BL/6 background were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Wild-type (wt)
C57BL/6 mice were obtained from Monash University
Animal Services (Melbourne, Australia).
Anti-GBM GN was initiated in mice by an IV injection
of 14 mg of sheep antimouse GBM globulin into the tail
vein. Renal injury and immune responses were assessed
21 days later. GN was induced in CD80−/− (N = 11),
CD86−/− (N = 8), CD80/86−/− (N = 12), and C57BL/6
control mice (N = 7) to investigate the role of CD80 and
CD86 during the development of crescentic GN. Nonim-
munized C57BL/6 mice (N = 8) provided normal controls
without GN. To determine whether the OX40/OX40-L
pathway provides a compensatory signal in the absence
of CD80 and CD86 costimulation, OX40-L was blocked
in wt and CD80/86−/− mice developing anti-GBM GN.
Each mouse received intraperitoneally (IP) 250 lg of
protein G purified inhibitory rat antimouse OX40-L
mAb [RM134L; provided by Dr. William Heath, Walter
and Eliza Hall Institute of Medical Research (WEHI),
Melbourne, Australia], which had been previously char-
acterized [13] or control Ab (protein G purified rat IgG).
Treatment was started on the day of anti-GBM globulin
administration and continued every second day until the
end of the experiment. The following groups of mice were
studied: (1) normal nonimmunized C57BL/6 mice with-
out GN (N = 8); (2) wt control mice with GN receiving
rat IgG (N = 7); (3) CD80/86−/− control mice with GN
receiving rat IgG (N = 9); (4) wt mice with GN receiving
anti-OX40-L mAb (N = 6); (5) CD80/86−/− mice with
GN receiving anti-OX40-L mAb (N = 8).
Assessment of renal injury
Glomerular crescent formation was assessed on peri-
odic acid–Schiff’s (PAS) reagent-stained, Bouin’s fixed 3-
lm thick paraffin sections. Glomeruli were considered to
exhibit crescent formation if 2 or more cell layers were ob-
served in Bowman’s space. For each animal, a minimum
of 50 glomeruli was counted to determine the percentage
of crescentic glomeruli. Proteinuria (mg protein/24 h) was
measured by a modified Bradford’s method on urine col-
lected during the final 24 hours of experiments. Serum
creatinine concentrations (lmol/L) were measured by an
enzymatic creatininase assay.
Glomerular accumulation of macrophages and
CD4+ T cells
Macrophages and CD4+ T cells were demonstrated
in glomeruli by 3-layer immunoperoxidase staining of
periodate-lysine paraformaldehyde (PLP)-fixed frozen 6-
lm thick kidney sections, as previously described [2, 27].
M1/70 mAb (rat IgG2b antimouse Mac-1; ATCC, Manas-
sas, VA, USA) was used for macrophages, whereas GK1.5
mAb (rat IgG2b antimouse CD4; ATCC) was used to de-
tect CD4+ T cells. Isotype-matched control Ig (rat IgG2b;
Pharmingen, San Diego, CA, USA) served as a negative
control. A minimum of 20 glomeruli were assessed per an-
imal and results expressed as cells per glomerular cross
section (c/gcs).
Assessment of circulating antigen-specific antibody levels
Circulating mouse antisheep globulin Ig levels (dilu-
tions 1:50 to 1:1600) were assessed by enzyme-linked
immunosorbent assay (ELISA) using serum collected
at the end of experiments, as previously described [28],
using horseradish peroxidase (HRP)-conjugated sheep
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antimouse Ig (1:2000; Amersham, Little Chalfont, UK).
HRP-conjugated goat antimouse IgG1 (1:4000; South-
ern Biotechnology Assoc., Birmingham, AL, USA) was
used to detect IgG1 (1:50 dilution). IgG2a (1:50 dilu-
tion) was detected with biotinylated rat antimouse IgG2a
(Pharmingen), followed by Extravidin (Sigma, Castle
Hill, NSW, Australia), biotinylated mouse anti-avidin Ab
(Sigma), and Extravidin-HRP (Sigma). Sera from nonim-
munized C57BL/6 mice were tested to provide baseline
Ab levels.
Production of IFN-c and IL-4 by cultured splenocytes
Spleens were removed from mice at the end of exper-
iments and single cell suspensions obtained. Splenocytes
(4×106 cells/mL/well) were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (10% fetal calf serum,
FCS) in the presence of 10 lg/mL sheep globulin for 72
hours. The concentrations of IFN-c and IL-4 in spleno-
cyte supernatants were measured by ELISA, as previ-
ously described [29], using the following mAbs: rat an-
timouse IFN-c (R46A2; Pharmingen), biotinylated rat
antimouse IFN-c (XMG1.2; Pharmingen), rat antimouse
IL-4 (11B11; ATCC), and rat antimouse IL-4 (BVD6;
DNAX, Palo Alto, CA, USA).
Apoptosis of CD4+ T cells
Apoptosis of CD4+ cells was assessed by Annexin-V
staining according to manufacturer’s instructions. Briefly,
isolated splenocytes were surface stained with PE-
conjugated antimouse CD4 Ab (L3T4; Pharmingen),
washed, and stained with a solution containing Annexin-
V-Flous (Roche Diagnostics, Penzberg, Germany) and
propidium iodide (PI). Analysis was performed by
flow cytometry. Results are expressed as percentage of
Annexin-V+ PI − CD4+ cells.
In vivo proliferation of CD4+ T cells
Mice were injected IP with 1 mg of bromodeoxyuri-
dine (BrdU) (Sigma) in saline 48, 36, 24, and 12 hours
before the end of experiments. As a negative control,
one mouse was injected with saline only. Isolated spleno-
cytes were surface stained with PE-conjugated antimouse
CD4 Ab (Pharmingen) for 1 hour on ice, washed, then
resuspened in 50 lL of cold 150 mmol/L NaCl and fixed
by dropwise addition of 0.5 mL cold 95% ethanol. They
were incubated on ice for 5 minutes, washed, then incu-
bated with phosphate-buffered saline (PBS) containing
1% paraformaldehyde and 0.01% Tween for 30 min-
utes at room temperature. Cells were pelleted and
incubated with 20 lL of fluoroscein isothiocyanate
(FITC)-conjugated anti-BrdU mAb/DNase (Becton
Dickinson, Franklin Lakes, NJ, USA) for 30 minutes at
room temperature in the dark. They were washed twice,
resuspended in PBS, and analyzed by flow cytometry. Re-
sults are expressed as percentage of BrdU+ CD4+ cells.
Expression of CD80, CD86, and OX40-L
Surface expression of CD80, CD86, and OX40-L on
splenocytes from mice injected with anti-GBM globulin
was determined by flow cytometry. Spleens were obtained
from mice and singe cell suspensions prepared. Cells
(1×106) were washed and incubated with hamster anti-
CD80 (16-10A1), rat anti-CD86 (GL1), or rat anti-OX40-
L mAb (RM134L). After washing, cells were incubated
with biotinylated rabbit antirat IgG Ab (Dako, Carpin-
teria, CA, USA) or biotin-conjugated rabbit antihamster
IgG (Sigma) diluted in 10% mouse serum, washed, incu-
bated with streptavidin-FITC (Dako), and analyzed by
flow cytometry.
Statistical analysis
Results are expressed as the mean ± SEM. One-way
analysis of variance (ANOVA), followed by Dunnett’s or
Bonferroni’s multiple comparison test, was used for sta-
tistical analysis (GraphPad Prism; GraphPad Software,
Inc., San Diego, CA, USA). Differences were considered
to be statistically significant if P < 0.05.
RESULTS
C57BL/6 mice develop crescentic GN
C57BL/6 control mice developed crescentic GN
(Figs. 1C and 2A), with 20.3 ± 2.5% of glomeruli be-
ing affected by crescent formation. They had significant
proteinuria (4.8 ± 1.0 mg/24hours vs. normal mice with-
out GN, 1.6 ± 0.2 mg/24hours, P < 0.05), as well as
macrophages (1.9 ± 0.2 c/gcs) and CD4+ T cells (0.23 ±
0.03 c/gcs) present in glomeruli.
CD80−/− mice develop attenuated GN
Development of GN in CD80−/− mice was attenu-
ated when compared to C57BL/6 controls. Glomerular
macrophages (1.9 ± 0.2 vs. 1.0 ± 0.16 c/gcs, P < 0.05,
Fig. 1A), CD4+ T cells (0.23 ± 0.03 vs. 0.10 ± 0.01 c/gcs,
P < 0.01, Fig. 1B), and crescents (20.3 ± 2.5 vs. 9.6 ±
1.8%, P < 0.01, Figs. 1C and 2B) were reduced in the
absence of CD80, although no changes were observed in
proteinuria (4.8 ± 1.0 vs. 5.8 ± 0.9 mg/24hours) or serum
creatinine (21.7 ± 0.9 vs. 22.6 ± 1.8 lmol/L). Compared
to C57BL/6 controls, CD80−/− mice had significantly en-
hanced CD4+ T-cell apoptosis (5.5 ± 0.4 vs. 11.3 ± 0.6%,
P < 0.0001, Fig. 3A) and decreased proliferation (16.7 ±
0.7 vs. 12.1 ± 1.2%, P = 0.017, Fig. 3C) in the spleen. IFN-
c (Fig. 4A) and IL-4 (Fig. 4B) production by cultured
splenocytes, as well as circulating Ig, IgG1, and IgG2a
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Fig. 1. Glomerular macrophages, CD4+ T cells, and crescents
in C57BL/6 mice with GN, and in CD80−/−, CD86−/−, and
CD80/86−/− mice. Macrophages (A), CD4+ T cells (B), and cres-
cents (C) were significantly reduced in CD80−/−, markedly increased
in CD86−/−, and unaffected in CD80/86−/− mice compared to con-
trols. ∗P < 0.05 vs. control; ∗∗P < 0.01 vs. control.
levels (Fig. 5A, Table 1) were not significantly affected in
CD80−/− mice.
GN is exacerbated in CD86−/− mice
Glomerular injury was augmented in CD86−/− mice
compared to C57BL/6 controls. CD86−/− mice had a
trend toward elevated proteinuria (4.8 ± 1.0 vs. 8.3 ±
1.4 mg/24hours, P = 0.06) and serum creatinine (21.7 ±
0.9 vs. 28.7 ± 6.4 lmol/L), and developed augmented
glomerular infiltration of macrophages (1.9 ± 0.2 vs. 3.3 ±
0.3 c/gcs, P < 0.01, Fig. 1A) and CD4+ T cells (0.23 ± 0.03
vs. 0.49 ± 0.07 c/gcs, P < 0.01, Fig. 1B), as well as increased
crescent formation (20.3 ± 2.5 vs. 29.2 ± 1.5%, P < 0.05,
Figs. 1C and 2C). Apoptosis of splenic CD4+ cells was
reduced in CD86−/− mice compared to C57BL/6 con-
trols (3.2 ± 0.1 vs. 1.7 ± 0.2%, P < 0.001, Fig. 3B), as
was proliferation (22.7 ± 2.2 vs. 13.9 ± 1.2%, P < 0.01,
Fig. 2. Representative photomicrographs of glomerular crescent for-
mation in wild-type C57BL/6 controls, CD80−/−, CD86−/−, and
CD80/86−/− mice developing anti-GBM GN. Crescents were assessed
by PAS and hematoxylin staining of 3-lm thick paraffin sections. Con-
trol mice (A, × 400) developed proliferative and crescentic GN, which
was markedly reduced in CD80−/− mice (B, × 400), significantly en-
hanced in CD86−/− mice (C, × 400), and unaffected in CD80/86−/−
mice (D, × 400).
Fig. 3D). CD86−/− mice had markedly enhanced spleno-
cyte IFN-c production (177 ± 86 vs. 1202 ± 383 pg/mL,
P < 0.01, Fig. 4A) and a significant decrease in IL-4
(12.4 ± 5.0 vs. 2.0 ± 1.5 pg/mL, P < 0.05, Fig. 4B). Ag-
specific total Ig (Fig. 5B) and IgG1 (Table 1) levels were
siginificantly reduced in CD86−/− mice, while IgG2a re-
mained unchanged (Table 1).
Crescentic GN develops in the absence of CD80
and CD86 costimulation
CD80/86−/− mice developed GN comparable to
C57BL/6 controls, as assessed by proteinuria (4.8 ± 1.0
vs. 6.2 ± 1.4 mg/24hours), crescents (Figs. 1C and 2D),
and glomerular macrophages (Fig. 1A) and CD4+ T cells
(Fig. 1B). They also had a trend toward increased serum
creatinine (21.7 ± 0.9 vs. 31.8 ± 4.2 lmol/L). Apoptosis
(3.2 ± 0.1 vs. 1.1 ± 0.1%, P < 0.001, Fig. 3B) and prolif-
eration (22.7 ± 2.2 vs. 12.2 ± 0.8%, P < 0.001, Fig. 3D)
of splenic CD4+ cells was reduced in CD80/86−/− mice
compared to C57BL/6 controls. CD80/86−/− mice had
decreased splenocyte production of IFN-c (177 ± 86 vs.
16 ± 7 pg/mL, P = 0.068, Fig. 4A) and IL-4 (12.4 ± 5.0 vs.
1.2 ± 0.6 pg/mL, P < 0.05, Fig. 4B) compared to C57BL/6
controls. Ag-specific total Ig (Fig. 5C) and IgG1 (Table 1)
were significantly attenuated in CD80/86−/− mice, while
IgG2a was unaffected (Table 1).
Blockade of OX40-L differentially affects disease
outcome in wild-type and CD80/86−/− mice
Inhibition of OX40-L in wt mice enhanced the develop-
ment of GN compared to wt controls receiving rat IgG,
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Fig. 3. Flow cytometric analysis of apoptosis and in vivo proliferation
of spleen CD4+ T cells from C57BL/6 controls, CD80−/−, CD86−/−,
and CD80/86−/− mice developing GN. Apoptosis was measured by
Annexin-V staining and proliferation by BrdU labeling. Compared to
controls, apoptosis was enhanced in CD80−/− (A) and decreased in
CD86−/− and CD80/86−/− mice (B). Proliferation was decreased in
all three groups of knockouts (B and D). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P <
0.001, # P < 0.0001.
as indicated by glomerular infiltration of macrophages
(0.9 ± 0.1 vs. 1.1 ± 0.04 c/gcs, P < 0.01, Fig. 6A) and
CD4+ T cells (0.41 ± 0.03 vs. 0.53 ± 0.03 c/gcs, P < 0.05,
Fig. 6B), as well as crescent formation (21.7 ± 0.6 vs.
33.7 ± 1.6%, P < 0.001, Figs. 6C, 7A and B) and a trend
toward increased proteinuria (4.4 ± 0.5 vs. 6.0 ± 0.4 mg/
24 h). Wt mice receiving anti-OX40-L Ab treatment had
increased production of IFN-c by Ag-stimulated spleno-
cytes (76 ± 2 vs. 252 ± 18 pg/mL, P < 0.001, Fig. 8A),
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Fig. 4. Production of IFN-c and IL-4 by splenocytes cultured in the
presence of sheep globulin for 72 hours from control mice with anti-
GBM GN and from mice deficient in CD80, CD86, and both CD80
and CD86. Levels of IFN-c (A) and IL-4 (B) were not significantly
different in CD80−/− mice compared to controls. CD86−/− mice had
significantly increased production of IFN-c and reduced IL-4, while the
production of both cytokines was markedly attenuated in CD80/86−/−
mice compared to controls. ∗P < 0.05 vs. control, ∗∗P < 0.01 vs. control,
# P = 0.06 vs. control.
while IL-4 levels (Fig. 8B) were not affected. Apoptosis
and proliferation of splenic CD4+ cells were not signifi-
cantly affected by anti-OX40-L Ab treatment compared
wt controls receiving rat IgG (Fig. 9). Ag-specific total
serum Ig (Fig. 10) and IgG1 (Table 2) levels were signifi-
cantly enhanced in wt mice treated with anti-OX40-L Ab
compared to wt controls receiving rat IgG, while IgG2a
(Table 2) was unaffected.
In contrast, blockade of OX40-L in CD80/86−/− mice
attenuated proteinuria (5.1±0.7 vs. 2.7±0.6 mg/24 hours,
P < 0.05) and crescent formation (23.2 ± 1.2 vs. 14.6 ±
1.1%, P < 0.001, Figs. 6C, 7C, and D), as well as glomeru-
lar accumulation of macrophages (0.9 ± 0.05 vs. 0.7 ±
0.06c/gcs, P < 0.05, Fig. 6A) and CD4+ T cells (0.41 ±
0.03 vs. 0.13 ± 0.02 c/gcs, P < 0.001, Fig. 6B) compared
to CD80/86−/− controls treated with rat IgG. Interest-
ingly, blockade of OX40-L in CD80/86−/− mice resulted
in enhanced apoptosis (1.1 ± 0.1 vs. 5.6 ± 0.5%, P <
0.001, Fig. 9A) and attenuated proliferation (12.2 ± 0.8
vs. 6.9 ± 0.6%, Fig. 9B) of splenic CD4+ cells compared
to CD80/86−/− controls receiving rat IgG. CD80/86−/−
mice treated with anti-OX40-L Ab had significantly di-
minished production of IFN-c and IL-4 by Ag-challenged
splenocytes compared to wt mice receiving rat IgG or
anti-OX40-L Ab; however, their IFN-c and IL-4 levels
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Fig. 5. Levels of circulating mouse anti-sheep globulin Ig in C57BL/6
controls with GN and in CD80−/−, CD86−/−, and CD80/86−/− mice.
Serum Ig levels were measured by ELISA and tested at 6 dilutions (1:50
to 1:1600). Baseline represents Ag-specific Ig levels in normal C57BL/6
mice without GN. Ig levels were not significantly different in CD80−/−
compared to controls (A), but were significantly reduced in CD86−/−
(P < 0.0001 at all dilutions, B) and CD80/86−/− mice (P < 0.0001 at all
dilutions, C) compared to controls.
were not different to CD80/86−/− controls receiving rat
IgG (Fig. 8). Similarly, serum levels of Ag-specific total
Ig (Fig. 10), as well as IgG1 and IgG2a (Table 2), were
markedly attenuated in CD80/86−/− mice treated with
anti-OX40-L Ab compared to wt mice receiving rat IgG
or anti-OX40-L Ab; however, they were not different
when compared to CD80/86−/− controls receiving rat
IgG.
Table 1. Circulating levels of antigen-specific IgG1 and IgG2a in
CD80−/−, CD86−/−, and CD80/86−/− mice
IgG1 IgG2a
Normal C57BL/6 0.006 ± 0.006 0.078 ± 0.010
C57BL/6 controls with GN 1.395 ± 0.191 0.252 ± 0.137
CD80−/− 1.042 ± 0.242 0.218 ± 0.116
CD86−/− 0.176 ± 0.084a 0.131 ± 0.043
CD80/86−/− 0.138 ± 0.036a 0.286 ± 0.187
Serum levels of IgG1 and IgG2a specific to sheep globulin were measured
by ELISA at a dilution of 1:50 in normal C57BL/6 mice without GN, C57BL/6
controls with GN, and in CD80−/−, CD86−/−, and CD80/86−/− mice. Results
are expressed as the mean OD450nm ± SEM.
aP < 0.0001 vs. C57BL/6 controls with GN.
Expression of CD80, CD86, and OX40-L
The expression of CD80 was not affected on spleno-
cytes from C57BL/6 compared to CD86−/− mice (2.3 ±
0.09 ×107 vs. 2.2 ± 0.04 ×107 cells). Similarly, CD86
expression was not different between C57BL/6 and
CD80−/− mice (1.0 ± 0.08 ×108 vs. 1.0 ± 0.06 ×108 cells).
OX40-L expression was reduced in CD80/86−/− com-
pared to C57BL/6 mice (9.4 ± 0.27 ×107 vs. 6.9 ± 0.15
×107 cells, P < 0.0001).
DISCUSSION
The aim of the present study was to investigate the
mechanisms by which CD80 and CD86 regulate the
development of Th1-driven, Ab-independent crescentic
anti-GBM globulin GN, and to determine the role of
an alternative costimulatory, OX40/OX40-L pathway in
crescentic GN in the absence of CD80 and CD86. Here
we show that CD80 and CD86 differentially regulate the
development of crescentic anti-GBM GN. Disease was
attenuated in the absence of CD80 and exacerbated in
the absence of CD86, suggesting that CD80 is pathogenic
and CD86 protective in crescentic GN. Similarly, block-
ing CD80 prevented, whereas inhibition of CD86 en-
hanced, EAE [11]. The results obtained in CD80−/− and
CD86−/− mice cannot be attributed to changes in CD86
and CD80 expression in these mice, respectively, as the
expression of CD80 was not different between C57BL/6-
and CD86-deficient mice, and CD86 expression was sim-
ilar between C57BL/6 and CD80−/− mice.
Alterations in the Th1/Th2 balance can affect the devel-
opment of crescentic GN [30]. CD80 and CD86 have been
shown to affect Th1/Th2 differentiation, preferentially
regulating Th1 and Th2 development, respectively [11,
31]. Attenuated development of GN in CD80−/− mice
cannot be attributed to changes in Th1/Th2 regulation,
as indicated by splenocyte IFN-c and IL-4 production,
and circulating IgG1 and IgG2a levels. However, reduced
disease correlated with increased CD4+ T cell apoptosis
and decreased proliferation, suggesting that CD80 plays
a pathogenic role in crescentic GN by enhancing T-cell
survival and expansion. Previous studies have shown that
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Fig. 6. Glomerular macrophages, CD4+ T cells, and crescents in wild-
type (wt) and CD80/86−/− mice receiving rat IgG or anti-OX40-L Ab.
Macrophages (A), CD4+ T cells (B), and crescents (C) were signifi-
cantly enhanced in wt mice treated with anti-OX40-L Ab compared to
wt controls receiving rat IgG, and markedly reduced in CD80/86−/−
mice treated with anti-OX40-L Ab compared to CD80/86−/− controls
receiving rat IgG. c/gcs, cells per glomerular cross section; wt rat Ig, wt
controls receiving rat IgG; KO rat Ig, CD80/86−/− controls receiving rat
IgG; wt aOX40L, wt mice receiving anti-OX40-L mAb; KO aOX40L,
CD80/86−/− mice receiving anti-OX40L mAb. ∗P < 0.05 vs. wt rat Ig,
∗∗P < 0.01 vs. wt rat Ig, ∗∗∗P < 0.001 vs. wt rat Ig, KO rat Ig, and wt
aOX40L, #P < 0.05 vs. KO rat Ig and P < 0.001 vs. wt aOX40L, ×P <
0.001 vs. wt rat Ig, •P < 0.01 vs. wt rat Ig and P < 0.001 vs. wt aOX40L
and vs. KO rat Ig.
Fig. 7. Representative photomicrographs of glomerular crescent for-
mation in wild-type (wt) and CD80/86−/− mice with anti-GBM GN
receiving either control Ab (rat IgG) or anti-OX40L mAb. Crescents
were assessed by PAS and hematoxylin staining of 3-lm thick paraffin
sections. (A) Wt controls receiving rat IgG (× 400); (B) wt mice receiv-
ing anti-OX40L Ab (× 400); (C) CD80/86−/− controls receiving rat
IgG (× 400); (D) CD80/86−/− mice receiving anti-OX40L Ab (× 400).
Anti-OX40L mAb treatment enhanced crescent formation in wt mice
compared to wt controls receiving rat IgG. CD80/86−/− mice treated
with anti-OX40L Ab attenuated crescent formation compared to wt
and CD80/86−/− mice receiving rat IgG.
B7 molecules can promote T-cell survival and expansion
and, as such, augment disease [8, 32–35].
In contrast, the absence of CD86 caused a shift to-
ward Th1 responses, as indicated by reduced IL-4 and
enhanced IFN-c production, and decreased IgG1 levels,
suggesting that CD86 plays a protective role in crescen-
tic GN by promoting Th2 and consequently attenuating
Th1 responses. Similarly, anti-CD86 mAb treatment in-
creased the severity of EAE by enhancing Th1 differen-
tiation [11]. These observations are consistent with the
majority of evidence demonstrating that CD86 engage-
ment is more critical for Th2 than Th1 responses [31, 36].
In contrast, when CD86 was blocked with mAb in anti-
GBM GN, a change in Th1/Th2 balance was not observed
[26], probably due to a transient and incomplete inhi-
bition of CD86. Proliferation and apoptosis of splenic
CD4+ T cells were both reduced to a similar extent in
CD86−/− mice, suggesting that enhanced disease in these
mice cannot be attributed to an increase in overall T-cell
viability. Decreased apoptosis in CD86−/− mice is sur-
prising because previous evidence has demonstrated that
B7 molecules promote T-cell survival [8, 32–35]; however,
as will be discussed later, this may be due to the compen-
satory role of the OX40/OX40-L costimulatory pathway.
Mice lacking both CD80 and CD86 had disease sim-
ilar to controls, suggesting that anti-GBM GN can fully
develop in the absence of CD80/86 costimulation. Other
immune-mediated diseases, such as experimental autoim-
mune myocarditis, can also develop in the absence of
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Fig. 8. Production of IFN-c and IL-4 by splenocytes cultured in the
presence of sheep globulin for 72 hours from wild-type (wt) and
CD80/86−/− mice receiving rat IgG or anti-OX40-L Ab. Anti-OX40-L
Ab treatment significantly increased IFN-c (A) and did not affect IL-4
(B) levels in wt mice. CD80/86−/− mice receiving anti-OX40-L Ab had
significantly reduced IFN-c and IL-4 compared to wt mice receiving
anti-OX40-L Ab, but similar levels of both cytokines when compared
to CD80/86−/− controls receiving rat IgG. wt rat Ig, wild-type controls
receiving rat IgG; KO rat Ig, CD80/86−/− controls receiving rat IgG;
wt aOX40L, wild-type mice receiving anti-OX40-L mAb; KO aOX40L,
CD80/86−/− mice receiving anti-OX40L mAb. ∗P < 0.001 vs. wt rat Ig
and vs. wt aOX40L, ∗∗∗P < 0.001 vs. wt rat Ig.
CD28-mediated costimulation [37]. Conversely, in other
models of GN, EAG, and lupus nephritis, disease was
ameliorated in the absence of CD80 and CD86 [18–20,
38]. It is possible that autoreactive T cells in EAG and lu-
pus nephritis are potentially more dependent on CD80/86
costimulation due to their weaker affinity for Ag because
CD28 costimulation is more critical under conditions
of suboptimal T-cell activation [39]. Attenuated EAG
and lupus nephritis were also associated with decreased
intrarenal Ab deposits, which are pathogenic in these
models of GN [40, 41], but are not required for the de-
velopment of anti-GBM GN [1].
CD80/86−/− mice developed GN comparable to con-
trols despite decreased production of IFN-c and IL-4.
However, proliferation (46% decrease) and, to a larger
extent, apoptosis (67% decrease) of splenic CD4+ T cells
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Fig. 9. Flow cytometric analysis of apoptosis and proliferation of
splenic CD4+ T cells from wild-type (wt) and CD80/86−/− mice
receiving anti-OX40-L Ab or rat IgG. Apoptosis was measured by
Annexin-V staining and proliferation by BrdU labeling. Blockade of
OX40-L in wt mice did not affect apoptosis (A) or proliferation (B)
of CD4+ cells compared to wt controls receiving rat IgG. Inhibition of
OX40-L in CD80/86−/− mice enhanced apoptosis (A) and decreased
proliferation (B) of CD4+ cells compared to CD80/86−/− controls re-
ceiving rat IgG. wt rat Ig, wild-type controls receiving rat IgG; KO rat
Ig, CD80/86−/− controls receiving rat IgG; wt aOX40L, wild-type mice
receiving anti-OX40-L mAb; KO aOX40L, CD80/86−/− mice receiv-
ing anti-OX40L mAb. ∗∗P < 0.001 vs. wt rat IgG, ∗∗∗P < 0.001 vs. wt rat
IgG, KO rat IgG, and KO aOX40L.
were significantly reduced in CD80/86-deficient mice,
suggesting that the overall increased survival of CD4+
cells in CD80/86−/− mice may explain why these mice
had disease similar to controls. Reduced apoptosis in
CD80/86−/− mice is unexpected; however, further data
from the current study demonstrate that this is due to
compensation by OX40-L–mediated costimulation.
To investigate whether the OX40/OX40-L pathway
is an alternative costimulatory pathway in the absence
of CD80 and CD86 during the development of anti-
GBM GN, OX40-L was blocked in wt and CD80/86−/−
mice developing anti-GBM GN. Inhibition of OX40-L
in wt mice exacerbated, whereas OX40-L blockade in
CD80/86−/− mice attenuated GN, suggesting that OX40-
L differentially regulates the development of GN de-
pending on the presence or absence of CD80 and CD86.
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Fig. 10. Antigen-specific circulating Ig in wild-type (wt) and
CD80/86−/− mice receiving either control rat IgG or anti-OX40-L
Ab. Serum Ig levels were measured by ELISA and tested at 4 dilu-
tions (1:50 to 1:1600). Baseline represents Ig levels in nonimmunized
C57BL/6 controls without GN. Inhibition of OX40-L significantly in-
creased Ig levels in wt mice (P < 0.01 vs. wt rat Ig at all dilutions). Ig
levels in CD80/86−/− mice were markedly attenuated by anti-OX40-L
Ab treatment (P < 0.001 vs. wt rat Ig and vs. wt aOX40L at all dilutions);
however, they were not different when compared to CD80/86−/− con-
trols receiving rat IgG. wt rat Ig, wt controls receiving rat IgG; KO rat
Ig, CD80/86−/− controls receiving rat IgG; wt aOX40L, wt mice re-
ceiving anti-OX40-L mAb; KO aOX40L, CD80/86−/− mice receiving
anti-OX40-L mAb.
Table 2. Circulating levels of antigen-specific IgG1 and IgG2a in
wild-type (wt) and CD80/86−/− mice receiving either rat IgG or
anti-OX40-L mAb
IgG1 IgG2a
Wt + rat IgGa 2.012 ± 0.124 0.966 ± 0.450
CD80/86−/− + rat IgGb 0.173 ± 0.129e 0.038 ± 0.009h
Wt + anti-OX40-L Abc 2.476 ± 0.033f 0.984 ± 0.455h
CD80/86−/− + anti-OX40-L Abd 0.021 ± 0.011g 0.006 ± 0.003h
Serum levels of IgG1 and IgG2a specific to sheep globulin were measured by
ELISA at a dilution of 1:50 in wt and CD80/86−/− mice receiving either rat IgG
or anti-OX40-L mAb. Results are expressed as the mean OD450nm ± SEM.
aWt + rat IgG: wild-type controls with GN receiving rat IgG.
bCD80/86−/− + rat IgG: CD80/86−/− controls with GN receiving rat IgG.
cWt + anti-OX40-L Ab: wild-type mice with GN receiving anti-OX40-L mAb.
dCD80/86−/− + anti-OX40-L Ab: CD80/86−/− mice with GN receiving
anti-OX40-L mAb.
eP < 0.001 vs. Wt + rat IgG; f P < 0.05 vs. Wt + rat IgG; g P < 0.001 vs. Wt +
rat IgG and vs. wt + anti-OX40-L Ab; h P > 0.05 vs. all the groups.
In the presence of CD80 and CD86, OX40-L attenuates
GN, whereas in their absence, it enhances disease, sug-
gesting that OX40/OX40-L signaling compensates for the
absence of CD80 and CD86. Similarly, blockade of OX40-
L reduced disease in EAE-susceptible CD28−/− mice,
whereas it had no effect on disease development in wt
controls [14]. Other costimulatory pathways, including
CD40/CD40-L and ICOS/ICOS-L, are not excluded from
playing a role in CD28-independent immune responses
inducing crescentic GN because they can also provide an
alternative activation signal to T cells in the absence of
B7-mediated costimulation [42–44].
Inhibition of OX40-L in wt mice resulted in elevated
IFN-c and unaffected IL-4 production by splenocytes,
indicating that, in the presence of CD80 and CD86,
OX40-L plays a protective role in GN by down-regulating
the Th1 response. In contrast, levels IFN-c and IL-4 in
CD80/86−/− mice treated with anti-OX40-L mAb were
comparable to those in CD80/86−/− controls receiving
rat IgG, suggesting that reduced disease in CD80/86−/−
mice treated with anti-OX40L Ab cannot be explained by
changes in cytokine production. Proliferation and apop-
tosis of CD4+ T cells were not affected by OX40-L
blockade in wt mice, suggesting that these mechanisms
are not responsible for exacerbated disease in these ani-
mals. Quite interestingly, however, inhibition of OX40-L
in CD80/86−/− mice enhanced CD4+ T-cell apoptosis
and decreased proliferation, implying that in the absence
of CD80 and CD86, OX40-L plays a pathogenic role in
GN by decreasing apoptosis and increasing proliferation
of T cells. These results indicate that reduced apopto-
sis in CD80/86−/− mice compared to wt controls is a
consequence of compensation by OX40-L signaling, and
is probably due to the absence of CD86 because mice
deficient in CD86 and not CD80 also had decreased apop-
tosis and enhanced disease. OX40-L expression was sig-
nificantly reduced in the absence of CD80 and CD86,
suggesting that the observed effects of OX40-L block-
ade in CD80/86−/− mice are real and would be even
greater if OX40-L expression was comparable between
CD80/86−/− and C57BL/6 mice.
A recent study by Takeda et al has demonstrated that
OX40 signaling is not only critical for activation of naı¨ve
nonregulatory T cells, but is also important for the sup-
pressive function of CD4+CD25+ regulatory T cells, or
Tregs [45]. Furthermore, it was shown that CD28 signal-
ing is required for OX40 to overcome Treg-mediated sup-
pression. These observations are, therefore, potentially
relevant to the results of the current study. However, we
found that, in GN, OX40-L is protective in the presence
and pathogenic in the absence of CD80/86, suggesting
that effect of OX40-L inhibition on Tregs is probably not
responsible for the differential role of OX40-L in wt com-
pared to CD80/86−/− mice.
Circulating Ig levels were not affected in CD80−/−
mice, but were reduced to baseline levels in the absence
of CD86 alone and both CD80 and CD86. These results
are consistent with previous studies demonstrating that
CD86 has a more dominant role in Ig production [23, 46],
and suggest that CD80 is not required, whereas CD86
is essential for T-cell–dependent humoral immunity. Al-
tered Ig levels, however, are not likely to explain disease
outcome in the current study because autologous Ab is
not required for the development of crescentic anti-GBM
GN [1]. In fact, the present study further confirms that
anti-GBM GN is Ab-independent because CD86−/−
mice, which had very little Ab, developed exacerbated
disease. In addition, this study shows that in the presence
of CD86-mediated signaling, OX40/OX40-L interaction
down-regulates Ab production. Collectively, these results
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suggest that CD86 and OX40-L differentially regulate
T-cell–dependent humoral immunity in crescentic GN.
CONCLUSION
The present study shows that CD80 and CD86 differ-
entially regulate the development of Th1-mediated, Ab-
independent crescentic anti-GBM GN and do so by dif-
ferent mechanisms. CD80 has a pathogenic role in this
disease by decreasing apoptosis and increasing prolifera-
tion of nephritogenic CD4+ T cells, whereas CD86 plays
a protective role by enhancing Th2 and attenuating Th1
responses. Furthermore, the current study demonstrates
that OX40-L differentially regulates the development of
GN depending on the presence or absence of CD80 and
CD86 and does so by different mechanisms. In the pres-
ence of CD80 and CD86, OX40-L has a protective role
by attenuating Th1 responses, whereas in the absence of
these molecules, it plays a pathogenic role by enhancing
survival and expansion of nephritogenic T cells. There-
fore, the OX40/OX40-L pathway is an alternative cos-
timulatory pathway for mediating immune responses that
induce crescentic GN in the absence of CD80 and CD86.
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